

## Polygenic Risk for Depression Increases Risk of Ischemic Stroke

### From the Stroke Genetics Network Study

Sylvia Wassertheil-Smoller, PhD; Qibin Qi, PhD; Tushar Dave, MS; Braxton D. Mitchell, PhD; Rebecca D. Jackson, MD; Simin Liu, MD; Ki Park, MD; Joel Salinas, MD, MBA, MSc; Erin C. Dunn, ScD; Enrique C. Leira, MD, MS; Huichun Xu, MD, PhD; Kathleen Ryan, MPH; Jordan W. Smoller, MD, ScD

**Background and Purpose**—Although depression is a risk factor for stroke in large prospective studies, it is unknown whether these conditions have a shared genetic basis.

**Methods**—We applied a polygenic risk score (PRS) for major depressive disorder derived from European ancestry analyses by the Psychiatric Genomics Consortium to a genome-wide association study of ischemic stroke in the Stroke Genetics Network of National Institute of Neurological Disorders and Stroke. Included in separate analyses were 12577 stroke cases and 25643 controls of European ancestry and 1353 cases and 2383 controls of African ancestry. We examined the association between depression PRS and ischemic stroke overall and with pathogenic subtypes using logistic regression analyses.

**Results**—The depression PRS was associated with higher risk of ischemic stroke overall in both European ( $P=0.025$ ) and African ancestry ( $P=0.011$ ) samples from the Stroke Genetics Network. Ischemic stroke risk increased by 3.0% (odds ratio, 1.03; 95% confidence interval, 1.00–1.05) for every 1 SD increase in PRS for those of European ancestry and by 8% (odds ratio, 1.08; 95% confidence interval, 1.04–1.13) for those of African ancestry. Among stroke subtypes, elevated risk of small artery occlusion was observed in both European and African ancestry samples. Depression PRS was also associated with higher risk of cardioembolic stroke in European ancestry and large artery atherosclerosis in African ancestry persons.

**Conclusions**—Higher polygenic risk for major depressive disorder is associated with increased risk of ischemic stroke overall and with small artery occlusion. Additional associations with ischemic stroke subtypes differed by ancestry. (*Stroke*. 2018;49:00-00. DOI: 10.1161/STROKEAHA.117.018857.)

**Key Words:** atherosclerosis ■ depression ■ genetics ■ risk ■ stroke

Major depressive disorder (MDD) is one of the most common psychiatric disorders worldwide, with a lifetime prevalence estimated to be 15%.<sup>1,2</sup> The prevalence of mild, moderate, or severe depressive symptoms was 20% in a national representative sample of US adults, with 7% reporting moderate or severe symptoms.<sup>3</sup> Numerous large-scale epidemiological studies have demonstrated that MDD or depressive symptoms prospectively predict increased risk of stroke in white, Asian, and black populations.<sup>4-8</sup>

Despite the consistency of multiple large cohort studies showing that a history of depression prospectively predicts

incident stroke, the mechanisms underlying this association have not been elucidated. Specifically, little is known about whether depression is a general risk factor for stroke or a more specific risk factor for hemorrhagic or ischemic stroke. Further, depression may be a cause of stroke or a prodromal symptom of an impending stroke may influence behaviors that increase risk of stroke or may relate indirectly to other unknown factors that increase both depression and stroke risk.

Genetic studies offer an important opportunity to evaluate shared pathogenic contributions to depression and stroke. Recent genome-wide association studies (GWAS) have enabled

Received July 27, 2017; final revision received December 11, 2017; accepted December 20, 2017.

From the Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY (S.W.-S., Q.Q.); University of Maryland School of Medicine, Baltimore (T.D., B.D.M., H.X., K.R.); Department of Medicine, Ohio State University, Columbus (R.D.J.); Department of Epidemiology (S.L.) and Department of Medicine (S.L.), Brown School of Public Health and Alpert Medical School, Providence, RI; Division of Cardiology, University of Florida, Gainesville (K.P.); Department of Neurology (J.S.) and Psychiatric and Neurodevelopmental Genetics Unit, Department of Psychiatry, Center for Genomic Medicine (E.C.D., J.W.S.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Neurology, Carver College of Medicine (E.C.L.) and Department of Epidemiology, College of Public Health (E.C.L.), University of Iowa, Iowa City.

Presented in part at the Berlin BRAIN Symposium, Berlin, April 1–4, 2017.

The online-only Data Supplement is available with this article at <http://stroke.ahajournals.org/lookup/suppl/doi:10.1161/STROKEAHA.117.018857/-/DC1>.

Correspondence to Sylvia Wassertheil-Smoller, PhD, Albert Einstein College of Medicine, 1312B Belfer Bldg, 1300 Morris Park Ave, Bronx, NY 10461. E-mail [sylvia.smoller@einstein.yu.edu](mailto:sylvia.smoller@einstein.yu.edu)

© 2018 American Heart Association, Inc.

Stroke is available at <http://stroke.ahajournals.org>

DOI: 10.1161/STROKEAHA.117.018857

the estimation of common variant heritability for complex traits (single nucleotide polymorphism [SNP] heritability or  $h^2_{\text{SNP}}$ ). Significant  $h^2_{\text{SNP}}$  estimates have been reported for both depression ( $\approx 5\%–20\%$ )<sup>9,10</sup> and stroke and its subtypes ( $\approx 20\%–40\%$ ).<sup>11–16</sup> In the present study, we used polygenic risk scores (PRS) derived from genetic analyses of MDD from the Psychiatric Genomics Consortium (PGC)<sup>17</sup> to examine whether genetic risk for depression is associated with ischemic stroke and its subtypes. As an alternative to testing, the effects of individual SNPs, PRS have been commonly used to evaluate whether genetic risk for one condition (eg, depression) is associated with risk for a second condition (eg, stroke). A PRS is the weighted sum of individual SNP effect sizes derived from a GWAS. An association of the PRS with the second trait is typically interpreted as evidence for pleiotropy—that is, a common set of genetic variants that jointly influence risk of both conditions.

PRS for depression have been created for different phenotypic definitions of depression.<sup>18</sup> A PRS for the clinical phenotype of MDD has been constructed by PGC's MDD Working Group<sup>17</sup> where a GWAS was performed on a discovery sample of 11 625 individuals (4984 cases of depression and 6641 controls). In the present report, we applied this PRS to participants in the Stroke Genetics Network (SiGN) to test whether genetic risk for MDD is associated with risk of stroke. SiGN also includes adjudicated cases of stroke subtypes by presumed mechanism, allowing us to examine whether genetic predisposition to depression is associated with pathogenic subtypes of stroke.

## Methods

### Population: SiGN

The Stroke Genetics Network of National Institute of Neurological Disorders and Stroke was launched in 2010 to identify genetic loci associated with ischemic stroke and its subtypes. The design, rationale, and primary GWAS findings from SiGN have been described elsewhere.<sup>19–21</sup> The present report is based on 13 930 ischemic stroke cases and 28 026 controls of European and African ancestry for whom a PRS for MDD was generated. Ischemic stroke cases were accrued from 24 genetic research centers across the United States and Europe. Among the 24 individual cohorts, informed consent procedures may have varied, but each had its own institutional review board approval. To remain compliant with institutional review board approvals at some sites, only summary statistics are publicly available at <http://www.cerebrovascularportal.org/>. A subset of the SiGN individual-level data that is institutional review board compliant is available at dbGaP (phs000615.v1.p1). Requests for analysis of the full set of individual-level data can be made through the authors (B.D.M.).

All SiGN GWAS were adjusted for sex and the top 10 principal components,<sup>21</sup> after matching cases and controls within multiple analytic strata based on ancestry and genotyping platform as previously described.<sup>22</sup>

Subtypes for ischemic stroke were standardized using the web-based causative classification of stroke system (CCS) that uses a validated algorithm to assign stroke subtypes according to presumed mechanism based on clinical and ancillary test findings and were developed to maximize interexaminer reliability in stroke classification while using the full diagnostic data set from a typical stroke workup. There are 2 major versions: CCS phenotypic (CCSp) and CCS causative (CCSc). The CCS phenotypic algorithm is a documentation of abnormal test findings and does not require judgments on the part of the adjudicator. CCSc algorithm involves the integration of symptoms, vascular risk factors, diagnostic test results, response to treatment, and prognosis and thus requires a decision-making process. We present CCS phenotypic in this article and but also present the results for CCSc algorithm in the [online-only Data Supplement](#).

Data were entered by trained and certified adjudicators at participating genetic research centers. TOAST (Trial of ORG 10 172 in Acute Stroke Treatment) stroke subtype classifications were also available, and the comparison between the CCS and TOAST classifications has been published,<sup>20</sup> indicating that the overall agreement was moderate and varied widely across study sites, ranging from 28% to 90%. Furthermore, the interrater reliability of TOAST is considerably lower than that of CCS, with  $\kappa$  ranging between 0.42 and 0.54, whereas CCS  $\kappa$  range between 0.8 and 0.9.<sup>23–29</sup> Thus, in this article, we use CCS because it is a uniform classification system using algorithms that are applied across many different international cohorts; however, we also present the TOAST results in the [online-only Data Supplement](#).

Genotyping was conducted at the Center for Inherited Diseases Research. Strokes were classified as being caused by large artery atherosclerosis, small artery occlusion (SAO), cardioembolic, other type or mixed type, or cryptogenic undetermined or unknown usually because of insufficient workup or imaging.

### Depression PRS and Its Application to SiGN Participants

The depression PRS was derived from GWAS results from the Major Depressive Disorder Working Group of the PGC.<sup>17</sup> The PGC GWAS analyzed >1.2 million SNPs in 18 759 cases and controls. The full set of PGC GWAS results can be found at <https://www.med.unc.edu/pgc/results-and-downloads>. The PGC association results were generated for 123 025 independent SNPs based on linkage disequilibrium structure. MDD risk alleles were designated as the allele for each SNP associated with higher MDD risk. Alleles were weighted by their  $\beta$  coefficients from the MDD association analysis. In the PGC analysis, multiple  $P$  value thresholds for the association of individual SNPs with MDD were applied for inclusion in the depression PRS (from  $P_i=0.001–0.5$ ). The  $P$  value threshold of 0.5 performed best in the PGC test sample and was highly significant in predicting MDD (with  $P<10^{-6}$ ) but accounted for only a small proportion of the variance with  $R^2$  of 0.6%. The SNP weights generated by the PGC were then used to generate PRS for subjects in the SiGN data set.

We extracted data for the PGC polygenic score SNPs from the SiGN data. For each SNP, we converted the genotype posterior probabilities into single allelic dosages according to Equation 1 below.

$$\text{Allelic Dosage (AD)} = 2 * P(\text{AA}) + 1 * P(\text{AB}) + 0 * P(\text{BB}) \quad (1)$$

where  $P(\text{AA})$ ,  $P(\text{AB})$ , and  $P(\text{BB})$  indicate probabilities of having genotype AA, AB, and BB, with allele A corresponding to the risk allele.

To obtain the weighted PRSs, we multiplied allelic dosage by the regression  $\beta$  coefficient and summed this product across all loci in the SNP set (see Equation 2):

$$\text{Polygenic risk score (PRS)} = \sum (\beta_i * \text{AD}_s) \quad (2)$$

where  $\beta_i$  indicates  $\beta$  value for the  $i_{\text{th}}$  SNP from the PGC analysis and  $\text{AD}_s$  indicates allelic dosage for SiGN subjects.

Logistic regression analyses were conducted to relate PRS to stroke and its subtypes, where stroke  $(0,1)=\beta_s$  (PRS), adjusted for analytic strata and sex.

### Statistical Analysis

Logistic regression models were applied to test the association between the 8 PRSs, generated by different inclusion probability criteria for the individual SNPs, with separate models for stroke and its subtypes. Analyses were conducted separately for SiGN subjects of European and African ancestry.

## Results

The analyses included 12 577 stroke cases and 25 643 controls of European ancestry and 1 353 stroke cases and 2 383 controls

**Table 1. Relationship Between Polygenic Risk for Depression and All Ischemic Stroke Using 8 Polygenic Risk Scores for Different Inclusion Criteria ( $P_T$ ) Into the PRS: European Ancestry Adults**

$P_T$	No. of SNPs Included in PRS	No. of SNPs (%) From PGC That Were Not Present in SiGN	$\beta_s$	SE	$P$ Values for $\beta_s$
0.001	427	2 (0.47)	0.000298	0.00025	0.233
0.01	3348	11 (0.33)	0.000176	0.000092	0.055
0.05	13 243	57 (0.43)	0.000073	0.000047	0.122
0.1	23 606	92 (0.39)	0.000053	0.000035	0.136
0.2	41 475	164 (0.39)	0.000046	0.000027	0.088
0.3	57 186	238 (0.41)	0.000043	0.000023	0.058
0.4	71 315	306 (0.43)	0.000050	0.000021	0.016
0.5	83 890	358 (0.42)	0.000043	0.000019	0.025

$n=12577$  cases; 25 643 controls.  $P_T$  represents  $P$  value threshold for SNP inclusion into the PRS.  $\beta_s$  relates PRS to stroke subtype, per unit of PRS. PGC indicates Psychiatric Genomics Consortium; PRS, polygenic risk score; SiGN, Stroke Genetics Network; and SNP, single nucleotide polymorphism.

of African ancestry. Age of onset of stroke was (mean $\pm$ SD) 65.5 $\pm$ 15; in cases, 53.9% were males, and in controls, 45.2% were males. Tables 1 and 2 show the  $\beta$  coefficients for PRS in European and African ancestry groups, respectively, for different SNP inclusion criteria in the PRS.

The MDD PRS was associated with overall risk of ischemic stroke for  $P_T=0.4$  and  $P_T=0.5$  in both European and African ancestry samples. We present the primary results for  $P_T=0.5$  because this threshold was most closely related to depression in the PGC target sample, but the results for  $P_T<0.4$ , which includes 71 315 SNPs, are also shown in the [online-only Data Supplement](#).

In the SNP set where the SNP inclusion criterion was  $P=0.5$  with 83 890 SNPs used in the SiGN PRS, an additional 358

**Table 2. Relationship Between Polygenic Risk for Depression and All Ischemic Stroke Using 8 Polygenic Risk Scores for Different Inclusion Criteria ( $P_T$ ) Into the PRS: African Ancestry Adults**

$P_T$	No. of SNPs Included in PRS	No. of SNPs (%) From PGC That Were Not Present in SiGN	$\beta_s$	SE	$P$ Values for $\beta_s$
0.001	427	2 (0.47)	0.000110	0.000771	0.886
0.01	3348	11 (0.33)	0.000688	0.000284	0.016
0.05	13 243	57 (0.43)	0.000105	0.000142	0.458
0.1	23 606	92 (0.39)	0.000181	0.000105	0.084
0.2	41 475	164 (0.39)	0.000098	0.000072	0.169
0.3	57 186	238 (0.41)	0.000102	0.000057	0.074
0.4	71 315	306 (0.43)	0.000132	0.000048	0.006
0.5	83 890	358 (0.42)	0.000108	0.000043	0.011

$n=1353$  cases; 2383 controls.  $P_T$  represents  $P$  value threshold for SNP inclusion into the PRS.  $\beta_s$  relates PRS to stroke subtype, per unit of PRS. PGC indicates Psychiatric Genomics Consortium; PRS, polygenic risk score; SiGN, Stroke Genetics Network; and SNP, single nucleotide polymorphism.

SNPs (0.42% of SNPs) available in the PGC depression PRS were unavailable in SiGN. Overall, for every 1 SD difference in PRS ( $P_T=0.5$ ) ischemic stroke risk increased by 3.0% (odds ratio, 1.03; 95% confidence interval, 1.00–1.05) in those of European ancestry (Table 3), whereas those of African ancestry had an 8% risk increase (odds ratio, 1.08; 95% confidence interval, 1.04–1.13; Table 4). The corresponding figures for  $P_T=0.4$  are similar (Tables I and II in the [online-only Data Supplement](#)).

For analyses of ischemic stroke subtypes, we limited PRS analyses to SNPs included based on  $P_T=0.5$ . In those of European ancestry (Table 3), polygenic risk for MDD was associated with SAO stroke ( $P<0.001$ ) and cardioembolic stroke ( $P<0.042$ ). In those of African ancestry (Table 4), the MDD PRS was associated with large artery atherosclerosis ( $P<0.032$ ) and SAO ( $P\leq 0.029$ ), despite the smaller sample of African ancestry cases. For each SD increase in PRS, the risk of SAO increased by 8% (odds ratio, 1.08; 95% confidence interval, 1.03–1.13) for those of European ancestry and by 9% (odds ratio, 1.09; 95% confidence interval, 1.01–1.19) for those of African ancestry. The results were similar when using the CCS classification (Tables III and IV in the [online-only Data Supplement](#)). The TOAST classification also showed a significant increase in risk of SAO of 5% and 10% per 1 SD increase in PRS in European and African samples, respectively ( $P<0.03$ ), but other subtypes generally did not reach statistical significance (Tables V and VI in the [online-only Data Supplement](#)).



## Discussion

Large epidemiological studies have demonstrated that depression is associated with increased risk of stroke; however, it has been unclear whether this phenotypic association reflects a shared genetic basis. To our knowledge, this is the first report of an association between genetic risk for depression and ischemic stroke subtypes, providing a potential mechanism underlying the link between these common conditions.

We used a PRS for MDD derived from a large European ancestry sample and applied it to GWAS results from the National Institute of Neurological Disorders and Stroke SiGN study (Stroke Genetics Network). We found that higher PRS for depression is associated with higher risk of ischemic stroke, particularly of the SAO subtype, in both European and African ancestry subsamples of SiGN. As the MDD PRS was derived from GWAS of European ancestry samples, these results suggest a transethnic association between polygenic risk for MDD and stroke. For every 1 SD difference in the PRS for MDD, overall ischemic stroke risk increased by 2.6% and 7.0% for those of European and African ancestry, respectively. Further, in those of European ancestry, the PRS was additionally associated with cardioembolic strokes, whereas in the African ancestry group, it was associated with the large artery atherosclerosis subtype. PRS was significantly associated with SAO in the CCS phenotypic, the CCS, and TOAST classification systems.

In contrast to our results, a recent large-scale analysis of genetic correlations among 24 psychiatric and neurological disorders conducted by the Brainstorm consortium, which included 10 307 ischemic stroke cases and 19 326 population-matched



**Table 3. Relationship Between PRS Based on 83 890 SNPs With Inclusion Criterion Into PRS of  $P < 0.5$ , by CCSp Stroke Subtype for European Ancestry Adults**

Phenotype (CCSp)	Total No. of Cases	Total No. of Controls	$\beta_s$	SE	$P$ Value for $\beta_s$	OR (95% CI) for Stroke, per 1 SD of PRS*= $e^{\beta_s \text{SD}}$
All stroke	12577	25643	0.000043	0.000019	0.025	1.03 (1.00–1.05)
LAA	2229	25643	0.000031	0.000038	0.406	1.02 (0.98–1.07)
SAO	2029	25643	0.000132	0.000039	0.001	1.08 (1.03–1.13)
CE	3400	25643	0.000065	0.000032	0.0419	1.04 (1.00–1.08)
Other	612	25643	0.000087	0.00007	0.205	1.05 (0.97–1.14)
Crypto	963	25643	0.000090	0.000056	0.106	1.06 (0.99–1.13)

CCSp is the causative classification system—phenotypic subcategory.  $\beta_s$  relate PRS to stroke subtype, per unit of PRS. CE indicates cardioembolic; CI, confidence interval; Crypto, cryptogenic; LAA, large artery atherosclerosis; OR, odds ratio; Other, other type or mixed type; PRS, polygenic risk score; SAO, small artery occlusion; SiGN, Stroke Genetics Network; and SNP, single nucleotide polymorphism.

\*1 SD of PRS in SiGN is  $\approx 600$  U.

controls from Metastroke, found no significant relationship between MDD and ischemic stroke.<sup>30</sup> There is some overlap of data with our SiGN cases and controls: 5247 of the total 16851 SiGN cases (31%) and 8034 of the 32473 SiGN controls (25%) were also part of Metastroke. The current report, however, is based on a subset of the larger SiGN samples after excluding those of Hispanic ancestry, resulting in 13930 cases of European or African ancestry and 28026 controls. On the basis of the total SiGN sample, one can assume that less than one third of the cases and controls used in this SiGN study overlap with those in the Brainstorm analysis. With regard to depression data, Brainstorm used a larger and more recent PGC-MDD data set, not available at the time of our analyses.

In addition, our analyses differ from those done in the Brainstorm consortium in several important aspects. First, we focused on the genetic relationship of MDD to subtypes of stroke that was not examined in the Brainstorm analysis. Second, we examined ischemic stroke subtypes defined by the CCS, a classification algorithm based on all relevant clinical and test information that has demonstrated improved reliability relative to the TOAST classification approach used in the Brainstorm analysis. Third, to examine cross-phenotype relationships, we use PRS, whereas the Brainstorm analysis used linkage disequilibrium score regression. Linkage disequilibrium score regression is used to estimate genetic

correlation using only summary statistics and can be less powerful in some contexts compared with methods that use individual-level genotype data. In addition, linkage disequilibrium score regression can estimate the genetic correlation of traits using data across the entire genome; in PRS analyses, the scores examined are subsets of SNPs, typically restricted to those in the upper tails of the distribution of GWAS results (ie, the  $P$  value thresholds are prespecified for inclusion of SNPs in the PRS). Thus, if the genetic overlap is concentrated in loci that are within the selected  $P$  value threshold, PRS analyses may be more likely to show significant effects than might be seen with a genome-wide linkage disequilibrium score regression; this may be relevant to our finding of a genetic relationship between MDD and stroke that was not seen in the Brainstorm analyses.

The underlying mechanism connecting the observed association between genetic predisposition to depression and ischemic stroke risk is unclear. Recent research on the stroke–depression relationship has focused on pathophysiologic mechanisms, including vascular dysfunction and neuroendocrine pathways and genetic predisposition. The vascular depression disconnection hypothesis is that focal ischemic white matter lesions can disrupt neural connections among regions regulating mood and cognition, contributing to the clinical symptomatology of depression.<sup>31,32</sup> Because the

**Table 4. Relationship Between PRS Based on 83 890 SNPs With Inclusion Criterion Into PRS of  $P < 0.5$  by CCSp Stroke Subtype for African Ancestry**

Phenotype (CCSp)	Total No. of Cases	Total No. of Controls	$\beta_s$	SE	$P$ Value for $\beta_s$	OR (95% CI) for Stroke, per 1 SD of PRS*= $e^{\beta_s \text{SD}}$
All stroke	1353	2383	0.000108	0.000039	0.001	1.08 (1.04–1.13)
LAA	220	2383	0.000191	0.000089	0.032	1.12 (1.01–1.25)
SAO	390	2383	0.000150	0.000069	0.029	1.09 (1.01–1.19)
CE	208	2383	−0.00002	0.000089	0.816	0.99 (0.89–1.10)
Other	106	2383	0.000155	0.000126	0.219	1.10 (0.95–1.27)
Crypto	133	2383	0.00012	0.000110	0.285	1.07 (0.94–1.22)

CCSp is the causative classification system—phenotypic subcategory.  $\beta_s$  relate PRS to stroke subtype, per unit of PRS. CE indicates cardioembolic; CI, confidence interval; Crypto, cryptogenic; LAA, large artery atherosclerosis; OR, odds ratio; Other, other type or mixed type; PRS, polygenic risk score; SAO, small artery occlusion; SiGN, Stroke Genetics Network; and SNP, single nucleotide polymorphism.

\*1 SD of PRS in SiGN is  $\approx 600$  U.

disconnection hypothesis depends on the strategic location of such small vessel lesions, it is possible that the strength of the genetic association observed is limited by the randomness of where these small vessel lesions occurred.<sup>33–35</sup> Interestingly, we found a consistent association between polygenic depression risk and the lacunar (small vessel) ischemic stroke mechanism across both ancestry groups.

A second possible mechanistic connection is a common pathway promoting inflammation, although prior evidence is limited. Several candidate gene studies have linked polymorphisms associated with proinflammatory responses in depression. Prior studies linked genetic polymorphisms that promote proinflammatory responses with depression.<sup>36–38</sup> Atherothrombotic (large artery stroke) has also been linked to proinflammatory genes.<sup>39</sup> Third, platelets and endothelial function may play a role in the association between depression and stroke risk. Studies of candidate genes in patients with depression and coronary disease have implicated platelet dysregulation and inflammation as causal mechanisms. Thus, increased stroke risk with depression may be mediated through excessive platelet activation.<sup>40,41</sup> Endothelial dysfunction may be related as a study of young women with subclinical depression found a significant association between depression and abnormal endothelial function assessed by pulse-wave amplitude assessment.<sup>42</sup> We observed evidence of association between MDD and atherothrombotic ischemic stroke only for individuals of European ancestry. The lack of association among those of African ancestry might be because of limited power in that sample or transethnic differences in the genetic pathogenesis of large artery atherosclerosis. Of note, the atherothrombotic type is more common in European ancestry patients.<sup>43</sup> Finally, another possible common mechanism is cerebrovascular dysregulation and hypoperfusion.<sup>31</sup>

An important strength of our study is the large number of strokes in both European and African ancestry individuals, which have been classified by subtype in a uniform manner, although we note several limitations of our study. Power to detect associations with certain subtypes was still limited by sample sizes. Power in African ancestry samples also may have been reduced by transethnic differences in the genetic basis of stroke. A PRS derived from an African ancestry GWAS might contain different SNPs and thus could show a stronger or different relationship to certain subtypes of stroke in African ancestry samples. However, it is noteworthy that a European-derived MDD PRS was also associated with stroke in those of African ancestry. In addition, the relationship of the PRS derived in the PGC to MDD explained only a small proportion of the variance of depression.

In the large National Institute of Neurological Disorders and Stroke SiGN study of 13 930 ischemic strokes, we found that higher polygenic risk for MDD depression is associated with higher risk of ischemic stroke overall and with small artery occlusion, both for those of European and African ancestry, supporting a common genetic basis between depression and stroke risk.

### Sources of Funding

This study was supported in part by the National Institutes of Health (NIH) grants U01 NS069208 and R01 NS100178.

Dr Wassertheil-Smoller is partially funded by National Heart, Lung, and Blood Institute (NHLBI) Women's Health Initiative (WHI), one of the cohorts that contributed data to the National Institute of Neurological Disorders and Stroke SiGN study (Stroke Genetics Network). The WHI program is funded by the NHLBI, NIH, US Department of Health and Human Services, through contracts HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C. Dr Salinas is supported by NIH grant T32NS048005 and by the Robert Katzman Research Training Fellowship in Alzheimer's and Dementia Research Cosponsored by the American Academy of Neurology, the American Brain Foundation, and the Alzheimer's Association. Dr Dunn is supported by NIH grant K01 MH102403. Dr Smoller is a partially supported as a Tepper Family MGH Research Scholar.

### Disclosures

None.

### References

- Hasin DS, Goodwin RD, Stinson FS, Grant BF. Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. *Arch Gen Psychiatry*. 2005;62:1097–1106. doi: 10.1001/archpsyc.62.10.1097.
- Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al; National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). *JAMA*. 2003;289:3095–3105. doi: 10.1001/jama.289.23.3095.
- Shim RS, Baltrus P, Ye J, Rust G. Prevalence, treatment, and control of depressive symptoms in the United States: results from the National Health and Nutrition Examination Survey (NHANES), 2005–2008. *J Am Board Fam Med*. 2011;24:33–38. doi: 10.3122/jabfm.2011.01.100121.
- Moise N, Khodneva Y, Richman J, Shimbo D, Kronish I, Safford MM. Elucidating the association between depressive symptoms, coronary heart disease, and stroke in black and white adults: the reasons for geographic and racial differences in stroke (regards) study. *J Am Heart Assoc*. 2016;5:e003767.
- Mathur R, Pérez-Pimar M, Foguet-Boreu Q, Ayis S, Ayerbe L. Risk of incident cardiovascular events amongst individuals with anxiety and depression: a prospective cohort study in the east London primary care database. *J Affect Disord*. 2016;206:41–47. doi: 10.1016/j.jad.2016.07.046.
- Daskalopoulou M, George J, Walters K, Osborn DP, Batty GD, Stogiannis D, et al. Depression as a risk factor for the initial presentation of twelve cardiac, cerebrovascular, and peripheral arterial diseases: data linkage study of 1.9 million women and men. *PLoS One*. 2016;11:e0153838. doi: 10.1371/journal.pone.0153838.
- Bos MJ, Lindén T, Koudstaal PJ, Hofman A, Skoog I, Breteler MM, et al. Depressive symptoms and risk of stroke: the Rotterdam study. *J Neurol Neurosurg Psychiatry*. 2008;79:997–1001. doi: 10.1136/jnnp.2007.134965.
- Sun J, Ma H, Yu C, Lv J, Guo Y, Bian Z, et al; China Kadoorie Biobank Collaborative Group. Association of major depressive episodes with stroke risk in a prospective study of 0.5 million Chinese adults. *Stroke*. 2016;47:2203–2208. doi: 10.1161/STROKEAHA.116.013512.
- Ge T, Chen CY, Neale BM, Sabuncu MR, Smoller JW. Phenome-wide heritability analysis of the UK Biobank. *PLoS Genet*. 2017;13:e1006711. doi: 10.1371/journal.pgen.1006711.
- Hyde CL, Nagle MW, Tian C, Chen X, Paciga SA, Wendland JR, et al. Identification of 15 genetic loci associated with risk of major depression in individuals of European descent. *Nat Genet*. 2016;48:1031–1036. doi: 10.1038/ng.3623.
- Traylor M, Rutten-Jacobs L, Curtis C, Patel H, Breen G, Newhouse S, et al. Genetics of stroke in a UK African ancestry case-control study: South London Ethnicity and Stroke Study. *Neurol Genet*. 2017;3:e142. doi: 10.1212/NXG.0000000000000142.
- Traylor M, Bevan S, Baron JC, Hassan A, Lewis CM, Markus HS. Genetic architecture of lacunar stroke. *Stroke*. 2015;46:2407–2412. doi: 10.1161/STROKEAHA.115.009485.
- Bevan S, Traylor M, Adib-Samii P, Malik R, Paul NL, Jackson C, et al. Genetic heritability of ischemic stroke and the contribution of

- previously reported candidate gene and genomewide associations. *Stroke*. 2012;43:3161–3167. doi: 10.1161/STROKEAHA.112.665760.
14. Holliday EG, Traylor M, Malik R, Bevan S, Falcone G, Hopewell JC, et al; Australian Stroke Genetics Collaborative; Wellcome Trust Case Control Consortium 2; International Stroke Genetics Consortium. Genetic overlap between diagnostic subtypes of ischemic stroke. *Stroke*. 2015;46:615–619. doi: 10.1161/STROKEAHA.114.007930.
  15. Bluher A, Devan WJ, Holliday EG, Nalls M, Parolo S, Bione S, et al. Heritability of young- and old-onset ischaemic stroke. *Eur J Neurol*. 2015;22:1488–1491. doi: 10.1111/ene.12827.
  16. Devan WJ, Falcone GJ, Anderson CD, Jagiella JM, Schmidt H, Hansen BM, et al; International Stroke Genetics Consortium. Heritability estimates identify a substantial genetic contribution to risk and outcome of intracerebral hemorrhage. *Stroke*. 2013;44:1578–1583. doi: 10.1161/STROKEAHA.111.000089.
  17. Ripke S, Wray NR, Lewis CM, Hamilton SP, Weissman MM, et al; Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium. A mega-analysis of genome-wide association studies for major depressive disorder. *Mol Psychiatry*. 2013;18:497–511. doi: 10.1038/mp.2012.21.
  18. Radloff LS. The CES-d scale: a self-report depression scale for research in the general population. *Appl Psychol Meas*. 1977;1:385–401.
  19. Meschia JF, Arnett DK, Ay H, Brown RD Jr, Benavente OR, Cole JW, et al; NINDS SiGN Study. Stroke Genetics Network (SiGN) study: design and rationale for a genome-wide association study of ischemic stroke subtypes. *Stroke*. 2013;44:2694–2702. doi: 10.1161/STROKEAHA.113.001857.
  20. McArdle PF, Kittner SJ, Ay H, Brown RD Jr, Meschia JF, Rundek T, et al; NINDS SiGN Study. Agreement between TOAST and CCS ischemic stroke classification: the NINDS SiGN study. *Neurology*. 2014;83:1653–1660. doi: 10.1212/WNL.0000000000000942.
  21. NINDS Stroke Genetics Network (SiGN); International Stroke Genetics Consortium (ISGC). Loci associated with ischaemic stroke and its subtypes (sign): a genome-wide association study. *Lancet Neurology*. 2015;15:174–184. doi: 10.1016/S1474-4422(15)00338-5.
  22. Pulit SL, Voight BF, de Bakker PI. Multiethnic genetic association studies improve power for locus discovery. *PLoS One*. 2010;5:e12600. doi: 10.1371/journal.pone.0012600.
  23. Gordon DL, Bendixen BH, Adams HP Jr, Clarke W, Kappelle LJ, Woolson RF. Interphysician agreement in the diagnosis of subtypes of acute ischemic stroke: implications for clinical trials. The TOAST Investigators. *Neurology*. 1993;43:1021–1027.
  24. Atiya M, Kurth T, Berger K, Buring JE, Kase CS; Women's Health Study. Interobserver agreement in the classification of stroke in the Women's Health Study. *Stroke*. 2003;34:565–567.
  25. Meschia JF, Barrett KM, Chukwudelunzu F, Brown WM, Case LD, Kissela BM, et al; Siblings with Ischemic Stroke Study (SWISS) Investigators. Interobserver agreement in the trial of org 10172 in acute stroke treatment classification of stroke based on retrospective medical record review. *J Stroke Cerebrovasc Dis*. 2006;15:266–272. doi: 10.1016/j.jstrokecerebrovasdis.2006.07.001.
  26. Ay H, Benner T, Arsava EM, Furie KL, Singhal AB, Jensen MB, et al. A computerized algorithm for etiologic classification of ischemic stroke: the Causative Classification of Stroke System. *Stroke*. 2007;38:2979–2984. doi: 10.1161/STROKEAHA.107.490896.
  27. Arsava EM, Ballabio E, Benner T, Cole JW, Delgado-Martinez MP, Dichgans M, et al; International Stroke Genetics Consortium. The causative classification of stroke system: an international reliability and optimization study. *Neurology*. 2010;75:1277–1284. doi: 10.1212/WNL.0b013e3181f612ce.
  28. Selvarajah JR, Graves M, Wainwright J, Jha A, Vail A, Tyrrell PJ. Classification of minor stroke: intra- and inter-observer reliability. *Cerebrovasc Dis*. 2009;27:209–214. doi: 10.1159/000196817.
  29. Goldstein LB, Jones MR, Matchar DB, Edwards LJ, Hoff J, Chilukuri V, et al. Improving the reliability of stroke subgroup classification using the trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria. *Stroke*. 2001;32:1091–1098.
  30. Anttila V, Bulik-Sullivan B, Finucane H, Walters R, Bras J, Duncan L, et al. Analysis of shared heritability in common disorders of the brain [preprint first posted online Apr 16, 2016]. *BioRxiv*. doi: 10.1101/048991. www.biorxiv.org/content/early/2017/09/06/048991.
  31. Taylor WD, Aizenstein HJ, Alexopoulos GS. The vascular depression hypothesis: mechanisms linking vascular disease with depression. *Mol Psychiatry*. 2013;18:963–974. doi: 10.1038/mp.2013.20.
  32. Alexopoulos GS. Frontostriatal and limbic dysfunction in late-life depression. *Am J Geriatr Psychiatry*. 2002;10:687–695.
  33. Taylor WD, Zhao Z, Ashley-Koch A, Payne ME, Steffens DC, Krishnan RR, et al. Fiber tract-specific white matter lesion severity findings in late-life depression and by AGTR1 A1166C genotype. *Hum Brain Mapp*. 2013;34:295–303. doi: 10.1002/hbm.21445.
  34. Sheline YI, Price JL, Vaishnavi SN, Mintun MA, Barch DM, Epstein AA, et al. Regional white matter hyperintensity burden in automated segmentation distinguishes late-life depressed subjects from comparison subjects matched for vascular risk factors. *Am J Psychiatry*. 2008;165:524–532. doi: 10.1176/appi.ajp.2007.07010175.
  35. Dalby RB, Chakravarty MM, Ahvidan J, Sørensen L, Frandsen J, Jonsdottir KY, et al. Localization of white-matter lesions and effect of vascular risk factors in late-onset major depression. *Psychol Med*. 2010;40:1389–1399. doi: 10.1017/S0033291709991656.
  36. Wong ML, Dong C, Maestre-Mesa J, Licinio J. Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response. *Mol Psychiatry*. 2008;13:800–812. doi: 10.1038/mp.2008.59.
  37. Cerri AP, Arosio B, Viazzoli C, Confalonieri R, Vergani C, Annoni G. The -308 (G/A) single nucleotide polymorphism in the TNF-alpha gene and the risk of major depression in the elderly. *Int J Geriatr Psychiatry*. 2010;25:219–223. doi: 10.1002/gps.2323.
  38. Hwang JP, Tsai SJ, Hong CJ, Yang CH, Hsu CD, Liou YJ. Interleukin-1 beta -511C/T genetic polymorphism is associated with age of onset of geriatric depression. *Neuromolecular Med*. 2009;11:322–327. doi: 10.1007/s12017-009-8078-x.
  39. Belfer I, Wu T, Hipp H, Walter J, Scully M, Nyquist PA, et al. Linkage of large-vessel carotid atherosclerotic stroke to inflammatory genes via a systematic screen. *Int J Stroke*. 2010;5:145–151. doi: 10.1111/j.1747-4949.2010.00422.x.
  40. Parakh K, Sakhuja A, Bhat U, Ziegelstein RC. Platelet function in patients with depression. *South Med J*. 2008;101:612–617. doi: 10.1097/SMJ.0b013e318172f732.
  41. Aschbacher K, Mills PJ, von Känel R, Hong S, Mausbach BT, Roepke SK, et al. Effects of depressive and anxious symptoms on norepinephrine and platelet P-selectin responses to acute psychological stress among elderly caregivers. *Brain Behav Immun*. 2008;22:493–502. doi: 10.1016/j.bbi.2007.10.002.
  42. Tomfohr LM, Martin TM, Miller GE. Symptoms of depression and impaired endothelial function in healthy adolescent women. *J Behav Med*. 2008;31:137–143. doi: 10.1007/s10865-007-9141-4.
  43. Trivedi MM, Ryan KA, Cole JW. Ethnic differences in ischemic stroke subtypes in young-onset stroke: the Stroke Prevention in Young Adults Study. *BMC Neurol*. 2015;15:221. doi: 10.1186/s12883-015-0461-7.

## Polygenic Risk for Depression Increases Risk of Ischemic Stroke: From the Stroke Genetics Network Study

Sylvia Wassertheil-Smoller, Qibin Qi, Tushar Dave, Braxton D. Mitchell, Rebecca D. Jackson, Simin Liu, Ki Park, Joel Salinas, Erin C. Dunn, Enrique C. Leira, Huichun Xu, Kathleen Ryan and Jordan W. Smoller

*Stroke*. published online February 8, 2018;

*Stroke* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2018 American Heart Association, Inc. All rights reserved.

Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://stroke.ahajournals.org/content/early/2018/02/07/STROKEAHA.117.018857>

Data Supplement (unedited) at:

<http://stroke.ahajournals.org/content/suppl/2018/02/07/STROKEAHA.117.018857.DC1>

**Permissions:** Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Stroke* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

**Reprints:** Information about reprints can be found online at:  
<http://www.lww.com/reprints>

**Subscriptions:** Information about subscribing to *Stroke* is online at:  
<http://stroke.ahajournals.org/subscriptions/>

**Polygenic Risk for Depression Increases Risk of Ischemic Stroke: from the Stroke Genetics Network (SiGN) Study  
Supplemental Material**

Supplemental Table I

**Relationship between PRS based on 71,315 SNP's with inclusion criterion into PRS of  $p < .4$ , by CCSp stroke subtype for European Ancestry Adults**

Phenotype (CCS)	Total N Cases	Total N Controls	Beta <sub>s</sub>	SE	P for Beta <sub>s</sub>	OR (95% CI) for stroke per 1 s.d of PRS* = $e^{\text{beta} * \text{s.d.}}$
<b>All stroke</b>	12577	25643	0.00005	0.000021	0.0157	1.03 (1.01, 1.06)
<b>LAA</b>	2229	25643	0.000036	0.000041	0.3786	1.02 (0.97, 1.07)
<b>SAO</b>	2029	25643	0.00015	0.000042	0.0004	1.09 (1.04, 1.15)
<b>CE</b>	3400	25643	0.00006	0.000034	0.0817	1.04 (1.00, 1.08)
<b>OTHER</b>	612	25643	0.00014	0.000076	0.0665	1.09 (0.99, 1.19)
<b>Crypto</b>	963	25643	0.000056	0.00006	0.3506	1.03 (0.96, 1.11)



## Supplemental Table II

**Relationship between PRS based on 71,315 SNP's with inclusion criterion into PRS of  $p < .4$ , by CCSp stroke subtype for African Ancestry Adults**

Phenotype (CCS)	Total N Cases	Total N Controls	Beta <sub>s</sub>	SE	P for Beta <sub>s</sub>	OR (95% CI) for stroke per 1 s.d of PRS* = $e^{\text{beta} * \text{s.d.}}$
<b>All stroke</b>	1353	2383	0.000132	0.000048	0.0062	1.08 (1.02, 1.15)
<b>LAA</b>	220	2383	0.000233	0.000101	0.0208	1.15 (1.02, 1.20)
<b>SAO</b>	390	2383	0.000207	0.000078	0.0078	1.13 (1.03, 1.24)
<b>CE</b>	208	2383	-0.000020	0.0001	0.8565	0.99 (0.88, 1.11)
<b>OTHER</b>	106	2383	0.000187	0.000142	0.1863	1.12 (0.95, 1.32)
<b>Crypto</b>	133	2383	0.000124	0.000124	0.3145	1.08 (0.93, 1.25)

## Supplemental Table III

**Relationship between PRS based on 83,890 SNP's with inclusion criterion into PRS of  $p < .5$ , by CCSc stroke subtype for European Ancestry Adults**

Phenotype (CCS)	Total N Cases	Total N Controls	Beta <sub>s</sub>	SE	P for Beta <sub>s</sub>	OR (95% CI) for stroke per 1 s.d of PRS* = $e^{\text{beta} * \text{s.d.}}$
<b>LAA</b>	<b>2207</b>	<b>25643</b>	<b>4.08E-07</b>	<b>0.000038</b>	<b>0.9915</b>	<b>1.00 (0.96, 1.05)</b>
<b>SAO</b>	<b>1881</b>	<b>25643</b>	<b>0.000134</b>	<b>0.000041</b>	<b>0.001</b>	<b>1.08 (1.03, 1.14)</b>
<b>CE</b>	<b>2835</b>	<b>25643</b>	<b>0.000038</b>	<b>0.000034</b>	<b>0.2623</b>	<b>1.02 (0.98, 1.06)</b>
<b>CRYPTO</b>	<b>1027</b>	<b>25643</b>	<b>0.000071</b>	<b>0.000054</b>	<b>0.1884</b>	<b>1.04 (0.98, 1.11)</b>
<b>UNDETERMINED</b>	<b>4031</b>	<b>25643</b>	<b>0.000054</b>	<b>0.000029</b>	<b>0.0645</b>	<b>1.03 (1.00, 1.07)</b>
<b>INCONCLUSIVE</b>	<b>2038</b>	<b>25643</b>	<b>0.000091</b>	<b>0.000039</b>	<b>0.0203</b>	<b>1.06 (1.01, 1.11)</b>

## Supplemental Table IV

**Relationship between PRS based on 83,890 SNP's with inclusion criterion into PRS of  $p < .5$ , by CCSc stroke subtype for African Ancestry Adults**

	<b>Total N Cases</b>	<b>Total N Controls</b>	<b>Betas</b>	<b>SE</b>	<b>P for Betas</b>	<b>OR (95% CI) for stroke per 1 s.d of PRS* = <math>e^{\text{beta} \times \text{s.d.}}</math></b>
<b>LAA</b>	<b>178</b>	<b>2383</b>	<b>0.000201</b>	<b>0.000098</b>	<b>0.0409</b>	<b>1.13 (1.01, 1.27)</b>
<b>SAO</b>	<b>381</b>	<b>2383</b>	<b>0.000127</b>	<b>0.000069</b>	<b>0.0675</b>	<b>1.08 (1.00, 1.17)</b>
<b>CE</b>	<b>165</b>	<b>2383</b>	<b>-2.3E-07</b>	<b>0.000099</b>	<b>0.9982</b>	<b>1.00 (0.89, 1.12)</b>
<b>CRYPTO</b>	<b>133</b>	<b>2383</b>	<b>0.000118</b>	<b>0.00011</b>	<b>0.1884</b>	<b>1.07 (0.94, 1.22)</b>
<b>UNDETERMINED</b>	<b>543</b>	<b>2383</b>	<b>0.000083</b>	<b>0.000059</b>	<b>0.1601</b>	<b>1.05 (0.98, 1.13)</b>
<b>INCONCLUSIVE</b>	<b>242</b>	<b>2383</b>	<b>0.00007</b>	<b>0.000084</b>	<b>0.4047</b>	<b>1.04 (0.94, 1.15)</b>

## Supplemental Table V

**Relationship between PRS based on 83,890 SNP's with inclusion criterion into PRS of  $p < .5$ , by TOAST stroke subtype for European Ancestry Adults**

	<b>Total N Cases</b>	<b>Total N Controls</b>	<b>Betas</b>	<b>SE</b>	<b>P for Betas</b>	<b>OR (95% CI) for stroke per 1 s.d of PRS* = <math>e^{\text{beta} \times \text{s.d.}}</math></b>
<b>LAA</b>	2193	25643	-0.000003	0.000039	0.399	1.00 (0.95, 1.95)
<b>SAO</b>	2252	25643	0.000084	0.000037	0.025	1.05 (1.01, 1.10)
<b>CE</b>	3138	25643	0.000052	0.000033	0.116	1.03 (0.99, 1.07)
<b>Other</b>	331	25643	0.000129	0.000095	0.171	1.08 (0.97, 1.21)
<b>UNDETERMINED</b>	3080	25643	0.000062	0.000033	0.060	1.04 (1.00, 1.08)



## Supplemental Table VI

**Relationship between PRS based on 83,890 SNP's with inclusion criterion into PRS of  $p < .5$ , by TOAST stroke subtype for African Ancestry Adults**

	<b>Total N Cases</b>	<b>Total N Controls</b>	<b>Betas</b>	<b>SE</b>	<b>P for Betas</b>	<b>OR (95% CI) for stroke per 1 s.d of PRS* = <math>e^{\text{beta} * \text{s.d.}}</math></b>
<b>LAA</b>	125	2383	0.000315	0.000117	0.007	1.21 (1.05, 1.39)
<b>SAO</b>	379	2383	0.000153	0.000069	0.028	1.10 (1.01, 1.19)
<b>CE</b>	195	2383	-0.00004	0.000091	0.624	0.98 (0.88, 1.09)
<b>Other</b>	42	2383	0.000225	0.000195	0.247	1.14 (0.91, 1.44)
<b>UNDETERMINED</b>	399	2383	0.000041	0.000068	0.550	1.02 (0.95, 1.11)